{"id":1013922,"date":"2026-10-27T07:35:14","date_gmt":"2026-10-27T11:35:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\/"},"modified":"2026-10-27T07:35:14","modified_gmt":"2026-10-27T11:35:14","slug":"trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\/","title":{"rendered":"Trevi Therapeutics to Participate in Stifel&#8217;s 2026 Healthcare Conference"},"content":{"rendered":"<h2>\nFireside chat with management on Wednesday, November 11, 2026, at 10:00 a.m. ET<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">NEW HAVEN, Conn., Oct.  27, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L_bgbsvFEfFNmL8uDSpsF6pl7bIAt6uTLfaoNr2SF2iZRAiZG0JNi-7sVIoCUi6BEjNBEjaUzjQAxcOlvN8qMOa1CBBSpQhaYK5KH9J9D8DVl5ZZUsinaZs98A3vu3nD\" rel=\"nofollow\" target=\"_blank\"><u>Trevi Therapeutics, Inc.<\/u><\/a>\u00a0(Nasdaq: TRVI),\u00a0a clinical-stage biopharmaceutical company developing the investigational\u00a0therapy\u00a0Haduvio\u2122\u00a0(oral nalbuphine ER)\u00a0for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD),\u00a0and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and David Hastings, Chief Financial Officer, will participate in a fireside chat at the Stifel 2026 Healthcare Conference on Wednesday, November 11, at 10:00 a.m. ET. The conference will be held from November 10-12 in New York, and Ms. Good and Mr. Hastings will also participate in investor meetings with attendees.<\/p>\n<p>To register for the fireside chat virtually, click <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jfsX4hebjcGlN6bKZkZ_LOSpE-wzyZYIn9nE00fLj3dCjzwqqUVaxIMtARhS7wk2mlR77N2cOX3HCK03oKmPjbfC5Nd5Qwg0_cx1TI_FqKpzhHcqV4UUX0c62ufV6wb_enAoS722IVV5mXmRFUv1Lvmm_3RfJ4PgbQfAvPsaNnZRLrDRIcxeBajnE3R94yks\" rel=\"nofollow\" target=\"_blank\">here<\/a>.<\/p>\n<p>\n        <strong>About Trevi Therapeutics, Inc.\u00a0<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio\u2122 (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). In clinical trials, Haduvio showed a\u00a0statistically-significant\u00a0reduction in cough frequency, consistent across baseline cough frequencies, and showed improvements in patient-reported outcomes, in both patients\u00a0with IPF-related chronic cough and in patients with RCC. Haduvio is believed to act on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.\u00a0\u00a0\u00a0<\/p>\n<p>Chronic\u00a0cough\u00a0in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~140,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients&#8217; quality of life.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>\u00a0\u00a0\u00a0\u00a0<br \/>RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting &gt;8\u2005weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip)\u00a0and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<p>The FDA has conditionally approved Haduvio as the trade name for nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.\u00a0\u00a0\u00a0\u00a0<br \/>\u00a0\u00a0\u00a0\u00a0<br \/>For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9tRMudF0eoj-I1-trHNiyop71c9BL38Y9ESg1rVqyYuKGQyvweN-D4BFOK2DaZAsabl5ngLMn3QQfI6fcmYSdH9invcmp_ZcOQmEqE6aG5nqOGp-Z6dl33gwQNSmWII6\" rel=\"nofollow\" target=\"_blank\"><u>www.TreviTherapeutics.com<\/u><\/a>\u00a0and follow Trevi on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8HPy0kJN2-jKCFaXl4m62WOyjOae5pP94MtD-_01cclCjjBzd9pRSx7FsVDuzD7ObCQ2QLunboX9BYOybYSWpA==\" rel=\"nofollow\" target=\"_blank\"><u>X<\/u><\/a>\u00a0(formerly Twitter) and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zCTda2bHnxnYBGnyJgET4cDU5vjCtzaN3TiR2k_dxWMdMZWA3KiZHsDFC9tx6axF7nb00wP0HtCvhesp9gejZTyzC7lPHXMK54CzBtLBDvGpR5166Q8gbPvMVBkJKBeL\" rel=\"nofollow\" target=\"_blank\"><u>LinkedIn<\/u><\/a>.\u00a0\u00a0\u00a0\u00a0<\/p>\n<p>\n        <strong>Investor Contact<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>Jonathan Carlson\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>Trevi Therapeutics,\u00a0Inc.\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>(203) 654 3286\u00a0\u00a0\u00a0\u00a0\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NUTK2B5FULYLFTJLS2rMM4c_CTzVITAYaK0JxEdCG1uIJ6ZIxMCz1cuG0z4SNn9SK4zHjaIejjwAH11gasUJDw==\" rel=\"nofollow\" target=\"_blank\"><u>IR@trevitx.com<\/u><\/a>\u00a0\u00a0<br \/>\u00a0\u00a0<br \/><strong>Media\u00a0Contact<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>Rosalia Scampoli\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>914-815-1465\u00a0\u00a0\u00a0\u00a0\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rjoYLBTbKN3hsvF1to265UAMN2QVr_wl9GgVGiyvd2zw5mrohLfkQuULyP-yfqySvm-xuoyLk1naeiW6YUWo9CtSpW9G3an1yyA2fyKCzKJVnjHasFYnvAYkJryNnvmp\" rel=\"nofollow\" target=\"_blank\"><u>rscampoli@marketcompr.com<\/u><\/a>\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzMwMyM3OTE2Nzc5IzIxMjUxMTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTExYzk5Y2YtODI3NC00ZTU5LWExNmItY2YwN2FmOGNmYTljLTExMzY2ODctMjAyNi0xMC0yNy1lbg==\/tiny\/Trevi-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Fireside chat with management on Wednesday, November 11, 2026, at 10:00 a.m. ET NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) &#8212; Trevi Therapeutics, Inc.\u00a0(Nasdaq: TRVI),\u00a0a clinical-stage biopharmaceutical company developing the investigational\u00a0therapy\u00a0Haduvio\u2122\u00a0(oral nalbuphine ER)\u00a0for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD),\u00a0and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and David Hastings, Chief Financial Officer, will participate in a fireside chat at the Stifel 2026 Healthcare Conference on Wednesday, November 11, at 10:00 a.m. ET. The conference will be held from November 10-12 in New York, and Ms. Good and Mr. Hastings will also participate in investor meetings with attendees. To register for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Trevi Therapeutics to Participate in Stifel&#8217;s 2026 Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1013922","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Trevi Therapeutics to Participate in Stifel&#039;s 2026 Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trevi Therapeutics to Participate in Stifel&#039;s 2026 Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Fireside chat with management on Wednesday, November 11, 2026, at 10:00 a.m. ET NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) &#8212; Trevi Therapeutics, Inc.\u00a0(Nasdaq: TRVI),\u00a0a clinical-stage biopharmaceutical company developing the investigational\u00a0therapy\u00a0Haduvio\u2122\u00a0(oral nalbuphine ER)\u00a0for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD),\u00a0and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and David Hastings, Chief Financial Officer, will participate in a fireside chat at the Stifel 2026 Healthcare Conference on Wednesday, November 11, at 10:00 a.m. ET. The conference will be held from November 10-12 in New York, and Ms. Good and Mr. Hastings will also participate in investor meetings with attendees. To register for &hellip; Continue reading &quot;Trevi Therapeutics to Participate in Stifel&#8217;s 2026 Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-27T11:35:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzMwMyM3OTE2Nzc5IzIxMjUxMTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Trevi Therapeutics to Participate in Stifel&#8217;s 2026 Healthcare Conference\",\"datePublished\":\"2026-10-27T11:35:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\\\/\"},\"wordCount\":514,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzMwMyM3OTE2Nzc5IzIxMjUxMTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\\\/\",\"name\":\"Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzMwMyM3OTE2Nzc5IzIxMjUxMTY=\",\"datePublished\":\"2026-10-27T11:35:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzMwMyM3OTE2Nzc5IzIxMjUxMTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzMwMyM3OTE2Nzc5IzIxMjUxMTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trevi Therapeutics to Participate in Stifel&#8217;s 2026 Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference - Market Newsdesk","og_description":"Fireside chat with management on Wednesday, November 11, 2026, at 10:00 a.m. ET NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) &#8212; Trevi Therapeutics, Inc.\u00a0(Nasdaq: TRVI),\u00a0a clinical-stage biopharmaceutical company developing the investigational\u00a0therapy\u00a0Haduvio\u2122\u00a0(oral nalbuphine ER)\u00a0for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD),\u00a0and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and David Hastings, Chief Financial Officer, will participate in a fireside chat at the Stifel 2026 Healthcare Conference on Wednesday, November 11, at 10:00 a.m. ET. The conference will be held from November 10-12 in New York, and Ms. Good and Mr. Hastings will also participate in investor meetings with attendees. To register for &hellip; Continue reading \"Trevi Therapeutics to Participate in Stifel&#8217;s 2026 Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-27T11:35:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzMwMyM3OTE2Nzc5IzIxMjUxMTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Trevi Therapeutics to Participate in Stifel&#8217;s 2026 Healthcare Conference","datePublished":"2026-10-27T11:35:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\/"},"wordCount":514,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzMwMyM3OTE2Nzc5IzIxMjUxMTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\/","name":"Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzMwMyM3OTE2Nzc5IzIxMjUxMTY=","datePublished":"2026-10-27T11:35:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzMwMyM3OTE2Nzc5IzIxMjUxMTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzMwMyM3OTE2Nzc5IzIxMjUxMTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-stifels-2026-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Trevi Therapeutics to Participate in Stifel&#8217;s 2026 Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1013922"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013922\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1013922"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1013922"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1013922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}